Inhibitory Effects of Trapping Agents of Sulfur Drug Reactive Intermediates against Major Human Cytochrome P450 Isoforms

被引:4
|
作者
Sodhi, Jasleen K. [1 ,2 ]
Delarosa, Erlie Marie [1 ,3 ]
Halladay, Jason S. [1 ,4 ]
Driscoll, James P. [1 ,5 ]
Mulder, Teresa [1 ]
Dansette, Patrick M. [6 ]
Khojasteh, S. Cyrus [1 ]
机构
[1] Genentech Inc, Dept Drug Metab & Pharmacokinet, 1 DNA Way MS 412a, San Francisco, CA 94080 USA
[2] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA
[3] MicroConstants Inc, Dept Drug Metab & Pharmacokinet, San Diego, CA 92121 USA
[4] Plexxikon Inc, Dept Drug Metab & Pharmacokinet, Berkeley, CA 94710 USA
[5] MyoKardia Inc, Dept Drug Metab & Pharmacokinet, San Francisco, CA 94080 USA
[6] Univ Paris 05, Lab Chim & Biochim Pharmacol & Toxicol, Sorbonne Paris Cite, CNRS,UMR 8601, F-75270 Paris 06, France
关键词
cytochrome P450; bioactivation; trapping agents; reactive metabolites; CYP inhibition; sulfur drug reactive intermediates; TANDEM MASS-SPECTROMETRY; CYSTEINE-SULFENIC ACID; IN-VITRO; BIOACTIVATION; METABOLITES; CLOPIDOGREL; TICLOPIDINE; SULFOXIDES; OXIDATION; REDOX;
D O I
10.3390/ijms18071553
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In some cases, the formation of reactive species from the metabolism of xenobiotics has been linked to toxicity and therefore it is imperative to detect potential bioactivation for candidate drugs during drug discovery. Reactive species can covalently bind to trapping agents in in vitro incubations of compound with human liver microsomes (HLM) fortified with beta-nicotinamide adenine dinucleotide phosphate (NADPH), resulting in a stable conjugate of trapping agent and reactive species, thereby facilitating analytical detection and providing evidence of short-lived reactive metabolites. Since reactive metabolites are typically generated by cytochrome P450 (CYP) oxidation, it is important to ensure high concentrations of trapping agents are not inhibiting the activities of CYP isoforms. Here we assessed the inhibitory properties of fourteen trapping agents against the major human CYP isoforms (CYP1A2, 2C9, 2C19, 2D6 and 3A). Based on our findings, eleven trapping agents displayed inhibition, three of which had IC50 values less than 1 mM (2-mercaptoethanol, N-methylmaleimide and N-ethylmaleimide (NEM)). Three trapping agents (dimedone, N-acetyl-lysine and arsenite) did not inhibit CYP isoforms at concentrations tested. To illustrate effects of CYP inhibition by trapping agents on reactive intermediate trapping, an example drug (ticlopidine) and trapping agent (NEM) were chosen for further studies. For the same amount of ticlopidine (1 mu M), increasing concentrations of the trapping agent NEM (0.007-40 mM) resulted in a bell-shaped response curve of NEM-trapped ticlopidine S-oxide (TSO-NEM), due to CYP inhibition by NEM. Thus, trapping studies should be designed to include several concentrations of trapping agent to ensure optimal trapping of reactive metabolites.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] In Silico Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 Isoforms
    Dmitriev, Alexander V.
    Rudik, Anastassia V.
    Karasev, Dmitry A.
    Pogodin, Pavel V.
    Lagunin, Alexey A.
    Filimonov, Dmitry A.
    Poroikov, Vladimir V.
    PHARMACEUTICS, 2021, 13 (04)
  • [42] Inhibitory effects of puerarin on cytochrome P450 subfamilies in vitro
    Kim J.Y.
    Kim J.S.
    Jung J.H.
    Chun P.
    Rhew K.Y.
    Oriental Pharmacy and Experimental Medicine, 2014, 14 (1): : 1 - 5
  • [43] The mRNA Expression of Cytochrome P450 Isoforms in Human Gastric Tissue
    Canturk, Pakize
    Caner, Vildan
    Oruc, Nevin
    Akarca, Ulus Salih
    Tepeli, Emre
    Cetin, Ozan G.
    Zencir, Sevil
    Topcu, Zeki
    HEPATO-GASTROENTEROLOGY, 2010, 57 (98) : 372 - 376
  • [44] Inhibition of Human Cytochrome P450 Isoforms by Mitragyna speciosa Extracts
    Ismail, Sabariah
    Hanapi, Nur Aziah
    Azizi, Juzaili
    Mansor, Sharif Mahsufi
    Mahmud, Roziahanim
    DRUG METABOLISM REVIEWS, 2010, 42 : 144 - 144
  • [45] Inhibition and inactivation of human cytochrome P450 isoforms by phenethyl isothiocyanate
    Nakajima, M
    Yoshida, R
    Shimada, N
    Yamazaki, H
    Yokoi, T
    DRUG METABOLISM AND DISPOSITION, 2001, 29 (08) : 1110 - 1113
  • [46] Identification of human cytochrome P450 isoforms involved in the metabolism of brotizolam
    Senda, C
    Kishimoto, W
    Sakai, K
    Nagakura, A
    Igarashi, T
    XENOBIOTICA, 1997, 27 (09) : 913 - 922
  • [47] Metabolism of Zaleplon by human hepatic microsomal cytochrome P450 isoforms
    Renwick, AB
    Mistry, H
    Ball, SE
    Walters, DG
    Kao, J
    Lake, BG
    XENOBIOTICA, 1998, 28 (04) : 337 - 348
  • [48] Contribution of cytochrome P450 isoforms to gliquidone metabolism in rats and human
    He, Fang
    Li, Yun
    Zeng, Caiwen
    Xia, Chunhua
    Xiong, Yuqing
    Zhang, Hong
    Huang, Shibo
    Liu, Mingyi
    XENOBIOTICA, 2014, 44 (03) : 229 - 234
  • [49] Identification and characterization of human cytochrome P450 isoforms interacting with pimozide
    Desta, Z
    Kerbusch, T
    Soukhova, N
    Richard, E
    Ko, JW
    Flockhart, DA
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1998, 285 (02): : 428 - 437
  • [50] Determination of the human cytochrome P450 isoforms involved in the metabolism of zolmitriptan
    Wild, MJ
    McKillop, D
    Butters, CJ
    XENOBIOTICA, 1999, 29 (08) : 847 - 857